WHY FOCUS ON APATHY? DIAGNOSIS, SYMPTOMS ASSESSMENT, METHODOLOGY FRAMEWORK. David S. Miller, MD, MA 2 September 2017 ISCTM

Similar documents
Cross-Diagnostic Disorders of Cognition/Motivation The Why and the What. George Garibaldi ISCTM, February 2014

ISCTM Apathy Working Group Session

Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease

Buy full version here - for $ 7.00

NEUROPSYCHOMETRIC TESTS

Number of Items. Response Categories. Part V: Specific Behavior Scales-Sleep Scales. Based on past month

CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE

Dementia and Fall Geriatric Interprofessional Training. Wael Hamade, MD, FAAFP

Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University

RESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH

The place for treatments of associated neuropsychiatric and other symptoms

CRITICALLY APPRAISED PAPER (CAP)

Alzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms. l The diagnosis of AD l Neuropsychiatric symptoms l Place of the ICT

Rational Medication Use in Dementia

American Board of Psychiatry and Neurology, Inc. Geriatric Psychiatry Core Competencies Outline

Neurogenic Disorders: Assessing/Managing Patient Motivation

March 29, 2017 Debra K. Smith, Ph.D. St. Charles Hospital Port Jefferson, New York

Transitions in Mental Health

Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia

Demystifying the Neuropsychological Evaluation Report. Clinical Neuropsychologist 17 March 2017 Program Director, Neurobehavioral Program

Professor Mary McCarron

The Personal and Societal Impact of the Dementia Ambient Care Multi-sensor Remote Monitoring Dementia Care System

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

DOCTOR/PHYSICIAN S CERTIFICATE OF MEDICAL EXAMINATION. In the Matter of the Guardianship of an Alleged Incapacitated Person

Why ICT are interesting for Frailty

Table e-1. MCI diagnosis criteria used by articles included in AAN MCI guideline. MCI diagnosis criteria used by included articles

Neuropsychiatric Syndromes

Neuropsychiatric Inventory Nursing Home Version (NPI-NH)

Neurocognitive Disorders Research to Emerging Therapies

Commi ee Lecture: Neurocogni ve Disorders TBI : Trauma c Brain Disorders. William L. Bograkos, MA, DO, FACOEP

FROM THE ALZHEIMER S ASSOCIATION INTERNATIONAL CONFERENCE 2018 NEW RESEARCH FOCUSES ON TREATING NON-COGNITIVE SYMPTOMS OF PEOPLE WITH DEMENTIA

Dementia. Assessing Brain Damage. Mental Status Examination

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients

ELND005 for Agitation and Aggression in Alzheimer s Disease (HARMONY-AD Study): Phase 2/3 design and clinical outcomes

Parkinson s Disease Foundation. PD ExpertBriefing: Apathy or Depression: Which One Is It?

SCIENTIFIC DISCUSSION

Dementia of the Alzheimer Type: the Drug Treatment Debate

DEMENTIA - COURSES AT A GLANCE (by date & area)

HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE?

DESIGN TYPE AND LEVEL OF EVIDENCE: Randomized controlled trial, Level I

Alzheimer's Disease - Activities of Daily Living Inventory AD-ADL

Clinical Mental Health Counseling (CMHC)

Neuropsychological profile of people living in squalor

For more information about how to cite these materials visit

Overview. Classification, Assessment, and Treatment of Childhood Disorders. Criteria for a Good Classification System

Parkinson s disease stakeholder workshop notes

Autism CRC Presentation - Longitudinal Study of Adults - 3DN Opportunities for Collaboration

PD ExpertBriefing: Cognition and PD: What You ve Always Wanted to Know But Were Too Afraid to Ask. Presented By: Tuesday, March 22, 2011 at 1:00 PM ET

SHARED CARE OF MCI/EARLY DEMENTIA

8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research

How we talk about Psychosis will shape what we think, feel and do about it.

The Case for Mental Health Check Ups

CRITICALLY APPRAISED PAPER (CAP)

Trial Description. PLEASE NOTE: This trial has been registered retrospectively. Title

Form D1: Clinician Diagnosis

The Industry s Views on Older Old Patients

Known as both a thief and murderer,

Cognitive Assessment 4/29/2015. Learning Objectives To be able to:

Background. In discussions of recruitment, the question was raised as to whether returning research results to subjects would help recruitment.

Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD

QUESTIONNAIRE: Finland

Attention Deficit/Hyperactivity Disorders: Are Children Being Overmedicated?

Mild Behavioral Impairment (MBI): Symptoms, Prodrome, or False Alarm?

CORRECTED COPY Department of Veterans Affairs VHA DIRECTIVE Veterans Health Administration Washington, DC December 9, 2010

Recommendations on Screening for Cognitive Impairment in Older Adults 2015

Behavior Problems: Dementia and Mental Illness in Long Term Care and Assisted Living Module III

What is Autism? -Those with the most severe disability need a lot of help with their daily lives whereas those that are least affected may not.

Definitional Criteria Working Group 1: Toward an Updated Nosology for HIVassociated Neurocognitive Disorders

Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Outcomes in GEM models of geriatric care: How do we measure success? Disclosure. Objectives. Geriatric Grand Rounds

CRITICALLY APPRAISED PAPER (CAP)

Caregiving for an Individual with Dementia: Beginning the Journey

Management of the Acutely Agitated Long Term Care Patient

9/8/2017 OBJECTIVES:

Office o f Disability Adjudication a Revie

IC ARTICLE MARRIAGE AND FAMILY THERAPISTS

Managing Pain. in Marfan Syndrome. Traci J. Speed, MD PhD Assistant Professor, Department of Psychiatry and Behavioral Sciences

RISK VS RIGHTS: SAFELY SUPPORTING CONSUMERS WITH SEXUAL TRAUMA HISTORIES DAVID K. ATTRYDE, MS LPC

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA 111)

Critically Appraising Geriatric ED Screening Instruments Opening Pandora s Box to Futility or Identifying Novel Opportunities?

Clinical Assessment. Client Name (Last, First, MI) ID # Medicaid # DOB: Age:

UDS version 3 Summary of major changes to UDS form packets

Natural Language Question Activity

Measurement, validity and reliability

TExES Deaf and Hard-of-Hearing (181) Test at a Glance

Chapter Three BRIDGE TO THE PSYCHOPATHOLOGIES

P20.2. Characteristics of different types of dementia and challenges for the clinician

Attention Deficit Hyperactivity Disorder

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

TTI Personal Talent Skills Inventory Coaching Report

UNTHSC TCOM Geriatric Competencies Curriculum Mapping Document

Enhancing the evidence-base on cognitive rehabilitation: what do we know and what do we need? Caroline van Heugten

Overview of Mental Health & Disorders. Dr Bhagwat Rajput MBBS DNB, Psychiatry World College Of Medical Sciences

Brain-based disorders in children, teens, and young adults: When to know there is a problem and what to do

Student Social Worker (End of Second Placement) Professional Capabilities Framework Evidence

A pan-european study on outcome measures for psychosocial intervention research in dementia

Classification of COS outcomes. Dr Susanna Dodd North West Hub for Trials Methodology Research University of Liverpool, UK

The Action Is In the Interaction

Transcription:

WHY FOCUS ON APATHY? DIAGNOSIS, SYMPTOMS ASSESSMENT, METHODOLOGY FRAMEWORK David S. Miller, MD, MA 2 September 2017 ISCTM

ALTERNATE TITLE: WHO'LL STOP THE TRAIN? David S. Miller, MD, MA 2 September 2017 ISCTM

Disclosure I am a full-time employee of Bracket

Addressing this Issue In the context of both the NPS-PIA and ISCTM BPSD Working Group

Estimated Prevalence of Apathy 2-5% in Cognitively Normal Persons 15-43% in MCI 36-51% in Mild AD 36 72% in AD (mild severe)

Mild Behavioral Impairment (MBI) Construct developed by the NPS-PIA Acquired in late life Sustained Impactful Can present in advance of any cognitive impairment or along with MCI APATHY is one of these symptoms

Apathy s Impact Leads to impairment in both ADLs and iadls Causes increased caregiver burden Is associated with poorer prognosis Can result in increased mortality

IMAGINE Subway Commuter train/acela TGV, Frecciarossa, Shinkansen You have a symptom that Heralds pending cognitive impairment Speeds the progression from NL cognition -> MCI -> Dementia diagnosis Results in significant caregiver distress Would you try to address it/treat it/slow or stop the train?

A Distinction Apathy Anhedonia Amotivation

As the field has evolved Definition of apathy operationalized Scales developed to assess apathy (and other NPS) in dementia Diagnostic criteria for apathy established Improved understanding of the etiology and subtypes

11 Diagnostic Criteria for apathy in AD A. Core feature of apathy, diminished motivation, present x 4 weeks B. 2/3 dimensions of apathy, reduced goal-directed behavior, goal-directed cognitive activity emotions C. functional impairments attributable to apathy D. exclusion criteria are specified to exclude symptoms and states that mimic apathy Inter-rater reliability high (kappa 0.93, p=.0001) Robert et al 2009, Mulin et al 2011

So, why the apathy re apathy? At the time of abstract submission a search of apathy and dementia on clinical trials.gov revealed only 11 studies And, how many were pharma initiated?

How many??? NONE

And, they varied a great deal Essentially, all were run by academic investigators Interventions included stimulants (modafinil and methylphenidate, ) dextromethorphan, rivastigmine, rtms, computerized training MMSEs as low as 10 Varying apathy severity Varying apathy criteria (NPI, AES, AES-C, FrSBe) Varying outcome measures (NPI, AES, AES-C, CGIC, FrSBe, Apathy Inventory, TUG, LARS, Reaction time on computerized cognitive testing, Motricity)

Can Pharma Trials be Done? YES Use Established Diagnostic Criteria Acknowledge the subtypes Carefully select outcome measure(s) Evaluate apathy alone or in combo with other NPS (eg depression)? Incorporate Neuroimaging and Biomarkers Consider pharmacologic challenge Address issues around placebo response Standardize Non-Pharmacologic Interventions Appreciate the source for determining ratings

Psychosocial interventions What were they and how often? How are those delivering the psychosocial therapies trained and vetted? Is the intervention standardized? Is the delivery of the intervention monitored? Are the therapies monitored for uptake, quality of implementation, and effect? If so, how? Is there any difference if the caregiver lives with the subject or not? Any impact on how they utilize and/or report on the outcome of the intervention(s)?

Data Quality Programs Identify and significantly reduce rater errors over the course of the trial ecoa improves standardization & further reduces errors Addition of audio reviews enhances ability to identify and remediate administration &/or scoring errors

ALL ABOARD??? The train is leaving the station

Apathy: Diagnostic Criteria Robert, P et al. Eur Psychiatry 2009. 24 (2): 98-194 Diagnosis requires fulfillment of criteria A, B, C and D A. Loss of or diminished motivation in comparison to the patient s previous level of functioning and which is not consistent with his age or culture. These changes in motivation may be reported by the patient himself or by the observations of others A. Presence of at least one symptom in at least two of the three following domains for a period of at least four weeks and present most of the time Domain B1 Behavior Domain B2 Cognition Domain B3 Emotion Loss of, or diminished, goal-directed behavior as evidenced by at least one of the following: Loss of, or diminished, goal-directed cognitive activity as evidenced by at least one of the following: Loss of, or diminished, emotion as evidenced by at least one of the following: Loss of self-initiated behavior (e.g., in starting conversation, doing basic tasks of day-to-day living, seeking social activities, communicating choices) Loss of spontaneous ideas and curiosity for routine and new events (i.e., challenging tasks, recent news, social opportunities, personal/family and social affairs). Loss of spontaneous emotion, observed or selfreported (e.g., subjective feeling of weak or absent emotions, or observation by others of a blunted affect) Loss of environment-stimulated behavior (e.g., in responding to conversation, participating in social activities) Loss of environment-stimulated ideas and curiosity for routine and new events (i.e., in the person s residence, neighborhood or community). Loss of emotional responsiveness to positive or negative stimuli or events (e.g., observerreports of unchanging affect, or of little emotional reaction to exciting events, personal loss, serious illness, emotional-laden news)

Apathy: Diagnostic Criteria cont d A. These symptoms (A & B) cause clinically significant impairment in personal, social, occupational, or other important areas of functioning A. The symptoms (A & B) are not exclusively explained or due to physical disabilities (e.g. blindness and loss of hearing), to motor disabilities, to diminished level of consciousness or to the direct physiological effects of a substance (e.g. drug of abuse, a medication)